Cabaletta Bio Q3 2022: cash $85.9M; CABA-201 IND submission planned 1H 2023; MuSK-CAART ODD granted

Cabaletta Bio, Inc.

2022-Q3 EPS reported -$1.29

Q3 2022 R&D expenses $8.2M, G&A $3.6M; cash and investments $85.9M, down from $122.2M at Dec 31, 2021.
Obtained exclusive worldwide license from IASO Bio for CD19 binder used in CABA-201, a fully human CD19-CAR T candidate; IND submission planned 1H 2023.
FDA granted Orphan Drug Designation to MuSK-CAART for MuSK- myasthenia gravis; first-in-human trial initiation expected Q4 2022.
Updated DesCAARTes interim data shows favorable safety; combination cohort (DSG3-CAART + IVIg/cyclophosphamide) 1-month data expected Q1 2023.
Cash runway through Q2 2024; initial CABA-201 clinical data expected by 1H 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cabaletta Bio, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-281920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.